“…We first hypothesized that S1133 (vaccine strain and reference genome) was most probably among the group of strains used to design the R-SPA oligos, and therefore, we observed a better performance with this isolate. To test this hypothesis, we compared the sequence homology of R-SPA primer R8N [ 13 ] with the ARV whole genomes obtained in this study, and we observed that the 5′ end of the ARV fragments (where R8N aligns) is very conserved, and therefore, it is very unlikely that the observed differences in the R-SPA performance were caused by different primer affinities between the ARV strains. Another potential explanation resides in the fact that although all the isolates were expanded in LMH cells for the same period of time, S1133 is cell-culture-adapted, so it could be disproportionately expanded compared to the other clinical isolates, yielding a higher viral titer, and therefore, more viral genomes for PCR amplification to act upon.…”